Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825 by Weller, M & Yung, W K A
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and
RTOG 0825
Weller, M; Yung, W K A
Abstract: Unspecified
DOI: 10.1093/neuonc/not106
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-79915
Accepted Version
Originally published at:
Weller, M; Yung, W K A (2013). Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio
and RTOG 0825. Neuro-Oncology, 15(8):971. DOI: 10.1093/neuonc/not106
Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 
0825 
 
The standard of care for patients with newly diagnosed glioblastoma was redefined in 
2005 when the EORTC NCIC trial showed the superiority of concomitant and 
maintenance temozolomide (TMZ) in addition to radiotherapy over radiotherapy 
alone. Since then numerous efforts to build on this new regimen have been explored, 
mostly testing the hypotheses that prolonged administration of TMZ or inhibition of 
angiogenesis will provide survival benefit. The most promising anti-angiogenesis 
agent was bevacizumab, a monoclonal antibody targeting vascular endothelial 
growth factor (VEGF). This was based on encouraging response rates and 
progression-free survival data upon landmark analyses at 6 months. Other VEGF-
targeting agents such as cediranib or VEGF trap were less convincing, both 
regarding safety and tolerability as well as efficacy. 
The conditional approval by the FDA in 2009 for bevacizumab in patients with 
recurrent glioblastoma was linked to the future demonstration of its efficacy in 
prospective trials in patients with newly diagnosed disease. Two such trials were 
performed largely in parallel, one by the RTOG (RTOG-0825) in the US, and one by 
Roche (AVAGlio), largely in Europe (1). Rather mature results from both trials were 
presented at the 2013 ASCO Meeting in Chicago (2,3). The results from both trials 
provide a rather uniform picture: Progression-free survival is significantly prolonged, 
quality of life during progression-free survival is preserved in the AVAGlio trial, but 
not in RTOG-0825, overall survival is not improved, and safety and tolerability are 
acceptable. Subgroup analyses, as available so far, do not identify specific 
subgroups of patients with a particularly convincing benefit from bevacizumab, and 
the comparison of both trials suggests no major impact of cross-over at progression. 
As it stands, the overall survival data from both trials do not support the routine use of 
bevacizumab in the upfront setting. This does not exclude the possibility that 
subgroup and molecular analyses may show a beneficial effect of bevacizumab in 
subgroups of patients with glioblastoma. Another important question is whether 
bevacizumab should remain available for patients with recurrent disease where it 
provides quality of life benefit for many patients and probably a progression-free 
survival benefit, too. Answers to other important questions are also pending. Are we 
sure that the gain in progression-free survival reflects a true impact on disease 
activity and not just altered imaging? If there is a true modification of disease biology, 
do some tumors become more invasive and more malignant? Is maintaining quality 
of life early in the course of disease worth paying the prize of rapid clinical 
deterioration later on, possibly based on induced refractoriness to all available further 
lines of treatment? Answering the latter question and deriving new strategies to 
prevent resistance or escape from VEGF inhibition appear to be the most promising 
road to success for adding VEGF inhibitors into current treatment paradigms for 
glioblastoma. 
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